We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
(-8.4%)
Cap. Flow
-$71.1M
Cap. Flow
% of AUM
-2.5%
Top 10 Holdings %
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$12.2M |
| 2 |
Stryker
SYK
|
+$10.9M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$8.83M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$8.51M |
| 5 |
Becton Dickinson
BDX
|
+$8.08M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$36.7M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$31.4M |
| 3 |
Merck
MRK
|
+$16.8M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$16.4M |
| 5 |
Danaher
DHR
|
+$14.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.64% |
| 2 | Real Estate | 3.21% |
| 3 | Industrials | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Elevance Health
ELV
$82B
| $7.19M | 0.25% |
14,644
| – | – |
|
77
Denali Therapeutics
DNLI
$3.84B
| $7.16M | 0.25% |
222,420
| – | – |
|
|
LTC
78
LTC Properties
LTC
$1.97B
| $7.01M | 0.25% |
182,293
| – | – |
|
79
HealthEquity
HQY
$8.78B
| $6.97M | 0.24% |
+103,314
| New | +$5.58M |
|
|
MRTX
80
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.89M | 0.24% |
83,784
| – | – |
|
81
Ionis Pharmaceuticals
IONS
$9.15B
| $6.51M | 0.23% |
175,680
| – | – |
|
82
Caribou Biosciences
CRBU
$156M
| $6.42M | 0.23% |
699,377
| – | – |
|
83
AMN Healthcare
AMN
$1.29B
| $6.38M | 0.22% |
61,201
| – | – |
|
84
Travere Therapeutics
TVTX
$5.21B
| $6.38M | 0.22% |
247,678
+34,809
| +16% | +$924K |
|
85
Sanofi
SNY
$102B
| $6.34M | 0.22% |
123,454
| – | – |
|
|
BPMC
86
DELISTED
Blueprint Medicines
BPMC
| $6.21M | 0.22% |
+97,253
| New | +$6.98M |
|
87
Arrowhead Research
ARWR
$12.6B
| $6.2M | 0.22% |
134,812
| – | – |
|
88
Revvity
RVTY
$12.4B
| $5.83M | 0.2% |
33,444
| – | – |
|
89
Smith & Nephew
SNN
$12.8B
| $5.8M | 0.2% |
181,710
| – | – |
|
90
Arvinas
ARVN
$581M
| $5.79M | 0.2% |
85,997
| – | – |
|
|
RCM
91
DELISTED
R1 RCM Inc. Common Stock
RCM
| $5.42M | 0.19% |
202,351
| – | – |
|
92
Qiagen
QGEN
$8.73B
| $5.29M | 0.19% |
101,713
| – | – |
|
93
Healthpeak Properties
DOC
$14.9B
| $5.16M | 0.18% |
150,392
| – | – |
|
94
Philips
PHG
$25.9B
| $5.03M | 0.18% |
199,498
| – | – |
|
95
Alkermes
ALKS
$8.33B
| $5M | 0.18% |
190,122
-87,187
| -31% | -$2.16M |
|
96
Acadia Healthcare
ACHC
$2.95B
| $4.74M | 0.17% |
+72,307
| New | +$4.2M |
|
97
Novavax
NVAX
$1.26B
| $4.7M | 0.17% |
63,800
| – | – |
|
98
Adaptive Biotechnologies
ADPT
$3.9B
| $4.69M | 0.16% |
337,722
| – | – |
|
99
Cytokinetics
CYTK
$10.7B
| $4.41M | 0.16% |
119,898
+27,027
| +29% | +$960K |
|
100
Teva Pharmaceuticals
TEVA
$40.1B
| $4.32M | 0.15% |
459,651
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
- Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
- Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
- Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
- Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
- Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
- Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.
Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.